Few micro-blood vessels in tumors may be the cause of perfusion defects in metastatic lymph nodes

NewsGuard 100/100 Score

If not caught quickly, cancer cells often spread to other organs in a process called metastasis. Lymph nodes (LNs) are the organs with the highest risk of metastasis. Metastasis in the LNs also influences cancer staging and treatment planning, and their detection is correlated with an increased risk of recurrence and mortality.

The most reliable sign of early-stage, non-enlarged LN metastasis is when perfusion - the passage of blood through the lymphatic system - shows defects, something detectable by CT scans, MRIs and ultrasound imaging devices.

Now, professor Tetsuya Kodama and his research group from Tohoku University Graduate School of Biomedical Engineering have revealed that the absence of small blood vessels in tumors may be the cause of impaired perfusion in non-enlarged, early-stage metastatic LNs.

To make their breakthrough, the research group injected cancer cells into mice bearing LNs of similar size to humans (about 10 mm). LNs injected with the cancer cells metastasized to connected LNs, where the researchers carefully tracked the cancer's progression using contrast-enhanced high-frequency ultrasound and micro-CT imaging.

We found that tumors forming with few micro-blood vessels are associated with defective perfusion."

Tetsuya Kodama, Professor, Tohoku University Graduate School of Biomedical Engineering

The finding could explain the low efficiency of systemic chemotherapy for metastatic LNs.

Their study also highlighted the importance of improving the spatial and density resolution of diagnostic imaging equipment to better improve the diagnosis and detection of LN metastasis, thereby curbing cancer-related mortality.

Source:
Journal reference:

Yamaki, T., et al. (2021) Characterizing perfusion defects in metastatic lymph nodes at an early stage using high-frequency ultrasound and micro-CT imaging. Clinical & Experimental Metastasis. doi.org/10.1007/s10585-021-10127-6.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New trials show promise for immune checkpoint blockers in early-stage lung cancer